The randomized TITAN and SPARTAN studies investigated the use of apalutamide in combination with androgen-deprivation therapy (ADT) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC), respectively. The combination was found to maintain health-related quality of life (HRQOL) and improve outcomes. ...
mCSPC
Advertisement
The trio highlights the results of a study on whether bone scans overstage PC compared with PSMA PET at initial staging.
A background on PSMA PET scans for staging of prostate cancer and comparison of accuracy of conventional vs PSMA PET imaging.
Research shed light on the safety and efficacy of pembrolizumab plus enzalutamide and ADT in patients with NHA-naïve mHSPC.
Investigators used plasma samples from the ORIOLE study to conduct a blind validation study based on this new research.
The PNI is commonly used as a prognostic factor for malignant tumors, but its potential use for prostate cancer is unknown.
SNMMI convened an autonomous workgroup to review prospective phase 2/3 clinical trials that used 177Lu-PSMA-617.
Multiple genitourinary oncology therapies are in the spotlight this week, with new US FDA indications on the horizon.
The phase 3 TITAN study assigned patients with mCSPC apalutamide or placebo with ADT to determine its effects on PFS and OS.
Advertisement
Prostate Cancer Knowledge Hubs
Conference Coverage
The retrospective analysis evaluated the data of patients who underwent multiagent chemotherapy.
At SUO 2023, Dr. Nicholas Corsi, UT Southwestern, presented one of the largest multinational studies on NAC in UTUC to date.
Almost half of all patients initiating 1L platinum-based chemotherapy were unable to receive maintenance avelumab treatment.
The generative AI model ChatGPT was fed a prostate cancer risk stratification algorithm.
The primary outcome was the potential for focal or hemi-gland ablation following analysis of the final pathologic specimen.
R-RPLND may offer lower morbidity and improved perioperative outcomes than O-RPLND for patients with CS II testicular cancer.
